12 October 2023
EMA/10588/2024 
Human Medicines Division
Statement indicating compliance with the agreed completed 
paediatric investigation plan
Medicinal product 
Lixiana/ edoxaban
Pharmaceutical form(s):
See Annex A of the CHMP Opinion
Strength(s):
See Annex A
Route(s) of administration:
See Annex A
Packaging and package 
See Annex A
size(s):
Number(s)in the Community 
See Annex A
Register of Medicinal Products:
Marketing Authorisation Holder (MAH):
Name and address of the MAH: Daiichi Sankyo Europe GmbH
Zielstattstrasse 48
81379 München
GERMANY
Procedure 
Procedure number:
EMEA/H/C/002629/WS2409/0042
Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and in 
accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that:
the development of this product has complied with all measures in the agreed paediatric investigation 
plan P/0423/2021. All studies in the agreed paediatric investigation plan P/0423/2021 were conducted 
after the entry into force of that Regulation,
-the Summary of Product Characteristics reflects the results of studies conducted in compliance with
this agreed paediatric investigation plan.
In accordance with Article 23a of Regulation (EC) No 1234/2008, this statement indicating compliance 
with the agreed completed paediatric investigation plan P/0423/2021 is included in the technical 
dossier.
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us 
Send us a question  Go to www.ema.europa.eu/contact  Telephone +31 (0)88 781 6000
An agency of the European Union  
